Watch the reverse cardiac remodelling video below to explore how cardiac damage can occur even in the absence of symptoms4
Reverse cardiac remodelling is linked to cardiac function improvements in HF patients5
ENTRESTO as first choice reduces cardiac stress and improves CV outcomes vs ACEi (enalapril)6,7
In a meta-analysis of 20 studies (N=10,175) of ENTRESTO vs placebo or ACEi/ARBs, ENTRESTO increased LVEF by nearly 5% (95% CI: 4.13–5.65) vs ACEi/ARBs,§8 and consistently led to:8
Improvements in key echocardiographic measures of reverse cardiac remodelling vs ACEi/ARBs
Therapeutic effect, with reverse cardiac remodelling benefits, manifest at 3 months and further increased over time
Greater benefit for patients treated with ENTRESTO compared to ACEi/ARBs as early as possible in the course of HFrEF
In EVALUATE-HF, ¶ENTRESTO showed incremental improvement in reverse cardiac remodelling vs ACEi (enalapril).#9
In EVALUATE-HF, neither enalapril nor ENTRESTO significantly reduced central aortic stiffness (primary endpoint).9
Learn more about how ENTRESTO can be used as your first choice in place of ACEi/ARB wherever your patients are in their HF journey1–3,6,9–17
Summary of the safety profile
The most commonly reported adverse events (AEs) during treatment with ENTRESTO were hypotension (17.6%), hyperkalaemia (11.6%) and renal impairment (10.1%). Angioedema was reported in patients treated with sacubitril/valsartan (0.5%).1,2
Common AE:
Anaemia, hypokalaemia, hypoglycaemia, dizziness, headache, syncope, vertigo, orthostatic hypotension, cough, diarrhoea, nausea, gastritis, renal failure (renal failure, acute renal failure), fatigue, asthenia.1,2
Very common AE:
Hyperkalaemia, hypotension, renal impairment.1,2
Adverse reactions are ranked by System organ class and then by frequency with the most frequent first, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Please click here for safety information
*PROVE-HF is a phase IV, single-arm, multicentre, open-label trial in the United States, of which 654 (82.4%) patients completed the 52-week study. This open-label study evaluated the effects of ENTRESTO on biomarkers, cardiac remodelling, and patient-reported outcomes in heart failure with reduced left ventricular ejection fraction. The correlation between the change in concentration of NT-proBNP and E/e′ was added to the statistical analysis plan prior to the database lock. The primary endpoint was the correlation of NT-proBNP concentrations with LVEF, LVEDVI, LVESVI and LAVI measures. At 12 months, NT-proBNP concentrations were associated with changes in these cardiac measures (all p<0.5). A secondary endpoint was the change in cardiac remodelling with Entresto treatment at 6 and 12 months.3
†LSM change from baseline.
‡For all comparisons.
§This result was obtained in a pooled data analysis of 10 out of the total 20 studies included in the meta-analysis (N=707).8
¶EVALUATE-HF was a multicentre, randomised, double-blind, double-dummy, parallel-group, active-controlled, forced-titration trial comparing ENTRESTO vs enalapril on changes in central aortic stiffness in patients with HFrEF over 12 weeks.9
#In EVALUATE-HF, neither enalapril nor ENTRESTO significantly reduced central aortic stiffness (remodelling of the aorta; primary endpoint). EVALUATE-HF included at randomisation n=61 NYHA Class I patients (13% of the total patients).9
ACEi, angiotensin-converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker inhibitor; ARNI, angiotensin receptor neprilysin inhibitor; CI, confidence interval; CV, cardiovascular; E/e’, ratio of early mitral inflow velocity to mitral annular early diastolic velocity; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LAVi, left atrial volume index; LSM, least squares mean; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end-systolic volume index; NT-proBNP, N-terminal-pro-brain natriuretic peptide; NYHA, New York Heart Association.
References:
- ENTRESTO Summary of Product Characteristics. Electronic medicines compendium website, GB. Available at: https://www.medicines.org.uk/emc/product/7751/smpc. (Accessed May 2023).
- ENTRESTO Summary of Product Characteristics. Electronic medicines compendium website, NI. Available at: https://www.emcmedicines.com/en-gb/northernireland/medicine?id=a1393009-... (Accessed May 2023).
- Januzzi JL Jr, et al. JAMA 2019;322(11):1085–1095.
- Mann DL, Bristow MR. Circulation 2005;111(21):2837–2849.
- Reis Filho JR, et al. Arq Bras Cardiol 2015;104(6):502–506.
- Velazquez EJ, et al. N Engl J Med 2019;380(6):539–548.
- Ambrosy AP, et al. J Am Coll Cardiol 2020;76(9):1034–1048.
- Wang Y, et al. J Am Heart Assoc 2019;8(13):e012272.
- Claggett B, et al. N Engl J Med 2015;373(23):2289–2290.
- Lewis EF, et al. Circ Heart Fail 2017;10(8):e003430.
- McMurray JJ, et al. N Engl J Med 2014;371:993–1004.
- Solomon SD, et al. JACC Heart Fail 2016;4(10):816–822.
- Chandra A, et al. JAMA Cardiol 2018;3(6):498–505.
- Desai AS, et al. JAMA 2019;322(11):1077–1084.
- Wachter R, et al. Eur J Heart Fail 2019;21(8):998–1007.
- Maddox TM, et al. J Am Coll Cardiol 2021;77:772–810.
- CaReMe UK HF algorithm. Available at: https://www.britishcardiovascularsociety.org/__data/assets/powerpoint_do.... (Accessed May 2023).